

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP2005/003081

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/11 C12Q1/68 G01N33/68 A61K38/00 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 2004/031412 A (ONCOTHERAPY SCIENCE, INC; JAPAN AS REPRESENTED BY THE PRESIDENT OF THE) 15 April 2004 (2004-04-15)</p> <p>page 45, lines 23-27</p> <p>page 46, lines 1-7</p> <p>page 67; table 5</p> <p style="text-align: center;">----- -/-</p>	28-50

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

10 August 2005

Date of mailing of the international search report

22/08/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Guarinos Viñals, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP2005/003081

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	ASHIDA SHINGO ET AL: "Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: Genome-wide gene-expression profiles of prostate cancers and PINs" CANCER RESEARCH, vol. 64, no. 17, 1 September 2004 (2004-09-01), pages 5963-5972, XP002339625 ISSN: 0008-5472 the whole document	1-27, 34-50
P,X	----- NAKAMURA TORU ET AL: "Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 23, no. 13, 25 March 2004 (2004-03-25), pages 2385-2400, XP002331614 ISSN: 0950-9232 page 2387, left-hand column, last paragraph page 2388; table 1 page 2389; figure 2 page 2399; table 5	28-30, 35-45,48
P,X	----- YAO V J ET AL: "VASCULAR BIOLOGY, ATHEROSCLEROSIS AND ENDOTHELIUM BIOLOGY TARGETING PANCREATIC ISLETS WITH PHAGE DISPLAY ASSISTED BY LASER PRESSURE CATAPULT MICRODISSECTION" AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 166, no. 2, February 2005 (2005-02), pages 625-636, XP009046949 ISSN: 0002-9440 page 629; table 1	28-30, 35-45,48
X	----- WO 95/28484 A (AMGEN INC) 26 October 1995 (1995-10-26) sequence SEQ ID NO 14 ----- -/-	9,10, 12-14, 24-26, 34-46, 48,49

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP2005/003081

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DOTTORI M ET AL: "EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 22, 27 October 1998 (1998-10-27), pages 13248-13253, XP002286945 ISSN: 0027-8424 page 13249, right-hand column, paragraph 3</p>	24, 35-44
X	<p>IRVING CAROL ET AL: "Progressive spatial restriction of Sek-1 and Krox-20 gene expression during hindbrain segmentation" DEVELOPMENTAL BIOLOGY, vol. 173, no. 1, 1996, pages 26-38, XP002339626 ISSN: 0012-1606 page 27, right-hand column, paragraph 2 page 30, left-hand column, paragraph 1</p>	26
X	<p>WO 02/30268 A (EOS BIOTECHNOLOGY, INC) 18 April 2002 (2002-04-18) sequence 69</p>	15-17, 20-22
X	<p>WO 03/009814 A (MILLENNIUM PHARMACEUTICALS, INC; SCHLEGEL, ROBERT; MONAHAN, JOHN, E; E) 6 February 2003 (2003-02-06) sequence 96</p>	15-17, 20-22
X	<p>US 6 506 607 B1 (SHYJAN ANDREW W) 14 January 2003 (2003-01-14) sequence 9</p>	15-17, 20-22
A	<p>US 6 071 697 A (SOSA-PINEDA ET AL) 6 June 2000 (2000-06-06)</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2005/003081

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 10 (as far as an "in vivo" method is concerned) and claims 15-22, 28 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compound.
2. ☒ Claims Nos.: 23, 27
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of Box II.1

Although claim 10 (as far as an "in vivo" method is concerned) and claims 15-22, 28 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compound.

Continuation of Box II.2

Claims Nos.: 23, 27

Present claims 23 and 27 relate to a compound defined by reference to a desirable characteristic or property, namely its capacity to be obtained by the screening method of any of claims 9-14.

The claims cover all compounds having this characteristic or property, whereas the application provides no support within the meaning of Article 6 PCT and no disclosure within the meaning of Article 5 PCT any of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently no search has been carried out for the subject-matter of claims 23 and 27.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP2005/003081

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2004031412	A	15-04-2004	AU 2003260966 A1	23-04-2004
			AU 2003263603 A1	23-04-2004
			CA 2500472 A1	15-04-2004
			CA 2500482 A1	15-04-2004
			EP 1556518 A2	27-07-2005
			EP 1549771 A2	06-07-2005
			WO 2004031411 A2	15-04-2004
			WO 2004031412 A2	15-04-2004
WO 9528484	A	26-10-1995	AU 702522 B2	25-02-1999
			AU 2292595 A	10-11-1995
			CA 2189028 A1	26-10-1995
			EP 1464706 A2	06-10-2004
			EP 0756627 A1	05-02-1997
			JP 9512167 T	09-12-1997
			JP 2004135670 A	13-05-2004
			WO 9528484 A1	26-10-1995
			US 5981245 A	09-11-1999
			US 5981246 A	09-11-1999
WO 0230268	A	18-04-2002	US 2002068036 A1	06-06-2002
			AU 1534502 A	22-04-2002
			CA 2425569 A1	18-04-2002
			EP 1474528 A2	10-11-2004
			JP 2005506033 T	03-03-2005
			MX PA03003151 A	19-08-2003
			WO 0230268 A2	18-04-2002
			US 2003087245 A1	08-05-2003
WO 03009814	A	06-02-2003	WO 03009814 A2	06-02-2003
			US 2003108963 A1	12-06-2003
US 6506607	B1	14-01-2003	US 2005100931 A1	12-05-2005
US 6071697	A	06-06-2000	DE 4225569 A1	10-02-1994
			US 6028184 A	22-02-2000
			AT 162721 T	15-02-1998
			CA 2141678 A1	17-02-1994
			DE 59308082 D1	05-03-1998
			DK 655926 T3	21-09-1998
			WO 9403196 A1	17-02-1994
			EP 0655926 A1	07-06-1995
			ES 2114615 T3	01-06-1998
			HK 1002531 A1	28-08-1998
			JP 7509477 T	19-10-1995
			US 5747250 A	05-05-1998
			AT 240406 T	15-05-2003
			AU 6291898 A	31-07-1998
			CA 2276460 A1	09-07-1998
			DE 69722035 D1	18-06-2003
			DE 69722035 T2	06-05-2004
			DK 958382 T3	25-08-2003
			WO 9829565 A2	09-07-1998
			EP 1348768 A2	01-10-2003
			EP 0958382 A2	24-11-1999
			JP 2000509610 T	02-08-2000
			JP 3631764 B2	23-03-2005